Search research articles
Contact Us
Filters
Showing results (21-30 of 50) with videos related to
Page
of 5
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
July 20, 2019
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer
Jessica A Hellyer, Henning Stehr, Millie Das, et al.
Journal of Palliative Medicine
|
September 6, 2019
Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial
Manisha Verma, Andrzej S Kosinski, Michael L Volk, et al.
Clinical Lung Cancer
|
June 26, 2022
Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens
Sarah Waliany, Heather Wakelee, Kavitha Ramchandran, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 21, 2021
Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC
Sarah Waliany, Han Zhu, Heather Wakelee, et al.
Clinical Lung Cancer
|
November 28, 2021
Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer
Jessica A Hellyer, Maya N White, Rebecca M Gardner, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 13, 2018
Oncologists' Views on Using Value to Guide Cancer Treatment Decisions
Risha Gidwani-Marszowski, Andrea L Nevedal, Douglas W Blayney, et al.
JTO Clinical and Research Reports
|
May 21, 2026
Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914]
Surbhi Singhal, Caressa Hui, Joel W Neal, et al.
JTO Clinical and Research Reports
|
November 19, 2025
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes
Surbhi Singhal, Caressa Hui, Joel W Neal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2019
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer
Youngtae Jeong, Jessica A Hellyer, Henning Stehr, et al.
JCO Oncology Practice
|
April 8, 2021
Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model
Joel W Neal, Mohana Roy, Kelly Bugos, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 50) with videos related to
Sort By:
Page
of 5
Lung Cancer (Amsterdam, Netherlands)
|
July 20, 2019
Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer
Jessica A Hellyer, Henning Stehr, Millie Das, et al.
Journal of Palliative Medicine
|
September 6, 2019
Introducing Palliative Care within the Treatment of End-Stage Liver Disease: The Study Protocol of a Cluster Randomized Controlled Trial
Manisha Verma, Andrzej S Kosinski, Michael L Volk, et al.
Clinical Lung Cancer
|
June 26, 2022
Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens
Sarah Waliany, Heather Wakelee, Kavitha Ramchandran, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 21, 2021
Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC
Sarah Waliany, Han Zhu, Heather Wakelee, et al.
Clinical Lung Cancer
|
November 28, 2021
Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer
Jessica A Hellyer, Maya N White, Rebecca M Gardner, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
August 13, 2018
Oncologists' Views on Using Value to Guide Cancer Treatment Decisions
Risha Gidwani-Marszowski, Andrea L Nevedal, Douglas W Blayney, et al.
JTO Clinical and Research Reports
|
May 21, 2026
Corrigendum to 'Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes' [JTO Clinical and Research Reports 6 (2025) 100914]
Surbhi Singhal, Caressa Hui, Joel W Neal, et al.
JTO Clinical and Research Reports
|
November 19, 2025
Central Nervous System Progression in Patients Receiving ALK-Targeted Central Nervous System-Penetrable Tyrosine Kinase Inhibitors: Treatment Patterns and Outcomes
Surbhi Singhal, Caressa Hui, Joel W Neal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 25, 2019
Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer
Youngtae Jeong, Jessica A Hellyer, Henning Stehr, et al.
JCO Oncology Practice
|
April 8, 2021
Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model
Joel W Neal, Mohana Roy, Kelly Bugos, et al.
Page
of 5